UNASSIGNED: e19510 Background: Survivor impressions of disease risk may vary with @entity1 demographics which may be important in designing survivorship programs for the increasing numbers of @entity0 survivors. PURPOSE: To evaluate survivor impressions surrounding @entity0 recurrence as well as risk for development of other @entity5 and non- @entity5 health problems and concerns. METHODS: A questionnaire was administered to 300 Stage I-III @entity0 @entity1 diagnosed from 1997-2007 to assess their impressions of recurrence risk as well as impressions of risk (lower, same, higher) for other diseases. Actual estimates were obtained from Adjuvant! Online and literature for comparison. RESULTS: @entity1 overestimated both local and distant recurrence risks: higher rates of distant recurrence than matched Adjuvant! estimates (p=.0001) were reported. Local and distant relapse perceptions were correlated (p<.0001) but were not associated with actual risks. No associations with race, annual income or education attainment were associated with @entity0 . Impressions of higher risk for second @entity5 varied (e.g. ovarian 42.7%, colon 31%, lung 28%); higher annual income and educational attainment were consistently associated with higher risk impressions for second @entity5 , but not for benign ailments. Chemotherapy recipients perceived higher risks for @entity170 (p=.011), @entity43 (p=.055), and @entity712 (p=.060). Hormonal agent recipients felt more at risk for @entity170 (p<.0001); of those, @entity440 recipients felt greater risk from endometrial (p=.016) and @entity43 (p=.029); @entity13558 -treated patients anticipated increased risk for @entity101 (p=.0009), @entity1007 (p=.0056), @entity712 (p=.028) and @entity625 (p=.065) as well as for local (p=.005) and distant (p=.0025) recurrence. CONCLUSIONS: All survivors tend to magnify their @entity0 relapse risk-local and distant. Those with higher incomes and education report higher second @entity5 risk but not @entity5 compared with others. Since perception may impact on compliance with surveillance and lifestyle choices, communicating risk needs careful attention in survivorship programs.

XXXX survivor perceptions regarding relapse and related disease risk.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity43 :: ('MESH:D010051', 'Disease') :: ['ovarian cancer'] @entity712 :: ('MESH:D006333', 'Disease') :: ['heart failure'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer', 'breast cancer recurrence perceptions'] @entity440 :: ('MESH:D013629', 'Chemical') :: ['tamoxifen'] @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancers', 'cancer', 'non-cancer disorders'] @entity1007 :: ('MESH:D006937', 'Disease') :: ['hypercholesterolemia'] @entity625 :: ('MESH:D001168', 'Disease') :: ['arthritis'] @entity170 :: ('MESH:D010024', 'Disease') :: ['osteoporosis'] @entity13558 :: ('MESH:C090450', 'Chemical') :: ['anastrazole']
@entity0 :: (MESH:D001943,Disease) :: ['Breast cancer']
